These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34952640)

  • 21. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
    Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK
    Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
    Dono A; Torres J; Nunez L; Arevalo O; Rodriguez-Quinteros JC; Riascos RF; Kamali A; Tandon N; Ballester LY; Esquenazi Y
    J Neurooncol; 2024 Mar; 167(1):99-109. PubMed ID: 38351343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
    Cantero D; Mollejo M; Sepúlveda JM; D'Haene N; Gutiérrez-Guamán MJ; Rodríguez de Lope Á; Fiaño C; Castresana JS; Lebrun L; Rey JA; Salmon I; Meléndez B; Hernández-Laín A
    Neurooncol Adv; 2020; 2(1):vdz059. PubMed ID: 32642724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
    Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
    Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
    Shibahara I; Sonoda Y; Suzuki H; Mayama A; Kanamori M; Saito R; Suzuki Y; Mashiyama S; Uenohara H; Watanabe M; Kumabe T; Tominaga T
    Brain Tumor Pathol; 2018 Jan; 35(1):10-18. PubMed ID: 29138945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.
    Barresi V; Simbolo M; Ciaparrone C; Pedron S; Mafficini A; Scarpa A
    Histopathology; 2022 Nov; 81(5):661-669. PubMed ID: 35945679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
    Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma.
    Stasik S; Juratli TA; Petzold A; Richter S; Zolal A; Schackert G; Dahl A; Krex D; Thiede C
    Neoplasia; 2020 Dec; 22(12):800-808. PubMed ID: 33142244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
    Ho WM; Chen CY; Chiang TW; Chuang TJ
    Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
    Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
    Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemistocytes in newly diagnosed glioblastoma multiforme: Clinical significance and practical implications in the modern era.
    Laviv Y; Berkowitz S; Kanner AK; Fichman S; Benouaich-Amiel A; Siegal T; Yust-Katz S
    J Clin Neurosci; 2021 Jun; 88():120-127. PubMed ID: 33992170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.
    Oh JE; Ohta T; Nonoguchi N; Satomi K; Capper D; Pierscianek D; Sure U; Vital A; Paulus W; Mittelbronn M; Antonelli M; Kleihues P; Giangaspero F; Ohgaki H
    Brain Pathol; 2016 Jul; 26(4):517-22. PubMed ID: 26443480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients.
    Neumann JE; Dorostkar MM; Korshunov A; Mawrin C; Koch A; Giese A; Schüller U
    J Neuropathol Exp Neurol; 2016 May; 75(5):408-14. PubMed ID: 26975364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.